🇺🇸 FDA
Patent

US 10471148

Progesterone formulations having a desirable PK profile

granted A61KA61K31/57A61K47/14

Quick answer

US patent 10471148 (Progesterone formulations having a desirable PK profile) held by Compass Therapeutics LLC expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Compass Therapeutics LLC
Grant date
Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
32
CPC classes
A61K, A61K31/57, A61K47/14, A61K9/4825, A61K9/4858